Viral Suppression Rates at 48 Weeks in People With HIV Starting Long-Acting Cabotegravir/Rilpivirine With Initial Viremia
Most Cited Paper
in HIV Research and Treatment
18 Months Post-Publication
Class of 2026
“Viral Suppression Rates at 48 Weeks in People With HIV Starting Long-Acting Cabotegravir/Rilpivirine With Initial Viremia”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/hiv-research-and-treatment/2026/
Topics
Long-acting injectable antiretroviral therapy · Long-acting CAB/RPV · HIV viremia · HIV viral suppression · Adherence · Virologic failure · emergent resistance mutations · RPV-associated resistance mutations · CAB-associated resistance mutations · lenacapavir · bictegravir/tenofovir alafenamide/emtricitabine · CD4 count · HIV viral load · 48-week durability · Long-acting injectable antiretroviral therapy · Ward 86 HIV clinic · People living with HIV (PLHIV) · Treatment switching
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited HIV Research and Treatment Papers, Class of 2026. https://pri.pepkio.com/top-papers/hiv-research-and-treatment/2026. Accessed 2026-07-21. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459